 BURLINGTON, Mass., July 30, 2020 GLOBE NEWSWIRE -- Flexion Therapeutics, Inc. Nasdaq:FLXN today announced that it will report its second-quarter 2020 financial results and recent business highlights after the close of the U.S. financial markets on Wednesday, August 5, 2020. About Flexion Therapeutics Flexion Therapeutics Nasdaq:FLXN is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Companys core values are focus, ingenuity, tenacity, transparency and fun. Visit flexiontherapeutics.com.Contact:Scott Young Vice President, Corporate Communications Investor Relations T: 781-305-7194 